AXL and esophageal squamous cell carcinoma: Over-expression of AXL also mediates resistance to treatment with the phosphoinositide -3-kinase-alpha (PI3Kα) inhibitor BYL719 by activating the EGFR/PKC/mTOR axis in ESCC [25].